8-K filing — Imunon, Inc. (IMNN)
Filed: 2026-10-27 AccNo: 0001493152-26-048625 Size: 16 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout in OVATION
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Imunon Enters Agreement to Sell ThermoDox® Rights to VoxelDox Therapeutics
Imunon, Inc. has announced an agreement to divest its rights to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc.
IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's Commitment to Its
Imunon Announces Exchange Of $1.2M Debt For Non-Convertible Series B Preferred Stock